Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of PDE4 in Alzheimer's Disease or Mild Cognitive Impairment
NCT07169630Phase 1Recruiting
- Sponsor
- National Institute of Mental Health
- Start
- Nov 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]PF-06445974 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by National Institute of Mental Health. Primary endpoint: PDE4B radioligand binding in medial temporal lobe at 48 months. Started Nov 2026; status: recruiting.
02
Drugs
[18F]PF-06445974
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07169630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169630.